Bitcoin price news this week is not about retail panic. It is about publicly traded companies that bet everything on a corporate crypto treasury strategy now facingBitcoin price news this week is not about retail panic. It is about publicly traded companies that bet everything on a corporate crypto treasury strategy now facing

Bitcoin Price News: Corporate Strategy Holders Face Balance Sheet Pressure as Pepeto Presale Fills the Gap and SOL Finds Floor

2026/03/07 11:30
5 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Bitcoin price news this week is not about retail panic. It is about publicly traded companies that bet everything on a corporate crypto treasury strategy now facing a very different reality. Meanwhile, smart retail money is finding a better path.

Bitcoin price news: Corporate BTC treasury holders face pressure as broader markets sell off

The latest Bitcoin price news shows that firms using a digital asset treasury strategy are absorbing sharp drops in their share prices as risk assets sell off broadly. Bitcoin has been trading near $71,000, having fallen from highs above $95,000 in late 2025. According to CoinDesk, falling share prices are limiting these companies’ ability to raise new capital to buy more BTC, creating a cycle of fear for institutional investors who had loaded up on the corporate treasury playbook. Reuters has reported sharp declines in shares of major crypto treasury firms, signaling that even the biggest holders are vulnerable when information asymmetry hits the market.

Bitcoin Price News: Corporate Strategy Holders Face Balance Sheet Pressure as Pepeto Presale Fills the Gap and SOL Finds Floor

Solana price analysis: SOL at $87.69 with recovery target of $110 to $130

Solana is trading at $87.69, having recovered from an intraday low near $67 earlier in the sell cycle. The first time SOL had traded that low since late 2023. The bounce shows buyers defending key support, but confidence remains thin as traders watch for a cleaner macro signal. According to CoinMarketCap, analysts put the near term SOL recovery target at $110 to $130 if Bitcoin reclaims $80,000 and ETF inflows resume. A $87.69 entry has solid long term value but the timing risk is real. SOL needs the market to cooperate. Not every opportunity requires that.

Bitcoin price news today reveals why retail needs an edge

Corporate treasury holders are struggling because they bet on price momentum without any way to protect themselves when momentum reverses. Retail traders are in the same position when they follow big names into crowded trades. The information gap is the real problem. Whales see order flow, on chain movements, and whale wallet activity before the crowd does. That gap defines who wins and who exits late.

Pepeto presale: The platform built for traders the corporate BTC story left behind

When corporate BTC strategies fail, the narrative shifts. Capital does not leave crypto. It rotates. It goes looking for the next asymmetric opportunity that is still priced early enough to matter. Pepeto is that opportunity right now.

The founders who built PEPE into a $7 billion market cap asset came back with a plan. PepetoSwap for native meme token trading, a cross chain bridge to aggregate liquidity across networks, and a full trading exchange for serious capital allocation.

All three have been announced by the team and are close to being ready. Dual audits from SolidProof and Coinsult found zero vulnerabilities. The presale is at $0.000000186 with a listing target of $0.0001.

A $425 entry at presale prices targets $228,225 at the 537x mark. SOL at $87.69 could deliver a 50 percent gain in a recovery. Pepeto with three products approaching launch and proven founders building from a $0.000000186 floor is in a category that SOL has not been in since its own presale days. That window does not come back.

Why Pepeto beats the Bitcoin price news narrative for return potential

Bitcoin price news this week shows corporate holders under pressure and retail sentiment near extreme fear. Pepeto has $7.391 million raised in this exact environment. That is smart money moving early, not late. The 537x return target, proven founders, and three approaching product launches make this the strongest risk reward ratio in the current presale market.

Click To Visit Pepeto Website To Enter The Presale

FAQs

What is the latest Bitcoin price news in 2026?

The latest Bitcoin price news shows corporate treasury holders under balance sheet pressure as BTC trades near $71,000 after falling from $95,000. Investors are rotating into high potential presales like Pepeto at $0.000000186 with a 537x return target.

Is Solana a good buy at $87.69?

Solana at $87.69 is a solid long term buy with a $110 to $130 recovery target if the macro environment improves. For investors seeking stronger near term return potential, Pepeto at $0.000000186 with a 537x listing target and three DeFi products approaching launch offers more asymmetric upside.

What crypto should I buy instead of following corporate Bitcoin strategies?

Instead of following corporate Bitcoin treasury strategies, investors should consider Pepeto. The presale is at $0.000000186 with a 537x return target at $0.0001, $7.391 million raised, PEPE founders behind the project, and dual zero vulnerability audits confirming smart contract safety.

Comments
Market Opportunity
Solana Logo
Solana Price(SOL)
$84.6
$84.6$84.6
-0.04%
USD
Solana (SOL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09